

using ABI Info, EconLit, PsychInfo, MEDLINE, CANCERLIT, AIDSLINE, HealthStar; databases were searched from 1990–2001. Articles identified comprised productivity measured by subjective (self-report questionnaires) and objective (computer-based tracking systems) techniques; subjective instruments included both generic and disease-specific measures. Identified instruments were evaluated on psychometric properties, generalizability to different populations, and administrator/respondent burden. **RESULTS:** Five generic subjective measures were identified—the Endicott Work Productivity Scale; Health and Labor Questionnaire; Health and Work Questionnaire; Work Limitations Questionnaire; and the Work Productivity and Activity Impairment Questionnaire (WPAI)—that could theoretically be used in any working population. All subjective instruments showed adequate to good reliability. However, these instruments were usually validated against other subjective measures (such as health-related quality of life), as a uniform measure of “productivity” does not exist. The WPAI was the most frequently used instrument and has also been modified to measure productivity reductions associated with specific diseases (e.g., allergic rhinitis, gastro-esophageal reflux disease). Objective assessments have been carried out to measure employee productivity for tasks where individual output could be quantified (e.g., claims processed, telephone inquiries handled). To avoid respondent bias, these studies utilized computer-based tracking systems to determine productivity reduction attributable to illness. **CONCLUSIONS:** Subjective and objective productivity assessments offer different benefits: while subjective instruments can be used in populations with different illnesses and/or jobs, objective measures minimize respondent bias but are associated with restricted generalizability and are burdensome to carry out in practice.

## CANCER

### CANCER—Economic Outcomes

#### PCN I

#### **COST ANALYSIS OF HLA-IDENTICAL SIBLING AND VOLUNTARY UNRELATED ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE MYELOCYTIC LEUKAEMIA OR ACUTE LYMPHOBLASTIC LEUKAEMIA**

Groot MT<sup>1</sup>, van Agthoven M<sup>1</sup>, Verdonck LF<sup>2</sup>, Löwenberg B<sup>3</sup>, Schattenberg AVMB<sup>4</sup>, Oudshoorn M<sup>5</sup>, Hagenbeek A<sup>2</sup>, Cornelissen JJ<sup>3</sup>, Uyl-de Groot C<sup>1</sup>, Willemze R<sup>5</sup>

<sup>1</sup>Erasmus University, Rotterdam, Netherlands; <sup>2</sup>University Medical Center Utrecht, Utrecht, Netherlands; <sup>3</sup>Erasmus MC, Rotterdam, Netherlands; <sup>4</sup>University Medical Center St. Radboud Nijmegen, Nijmegen, Netherlands; <sup>5</sup>Leiden University Medical Center, Leiden, Netherlands

**OBJECTIVE:** Allogeneic stem cell transplantations (SCT) for leukaemias are known to be one of the most

expensive medical procedures. In the Netherlands, a few licensed hospitals perform allogeneic SCT. However, the budgets they receive are not sufficient (for instance due to the application of donor lymphocyte infusions). We calculated the direct medical costs of patients who underwent allogeneic SCT to support a budget revision. **METHODS:** Costs of HLA-identical sibling bone marrow transplantation (BMT), bone marrow transplantation from a Matched Unrelated Donor (MUD) and peripheral blood stem cell transplantation (PBSCT) were identified. Costs were determined by two complementary methods. First, medical consumption for these patients was determined and multiplied by the unit costs of each of the items. Second, a structural program for allogeneic transplantations brings along costs that are not expressed in the registration of the medical consumption of patients (e.g. HLA-typing and selection of the unrelated donor). The costs of these items were identified in cooperation with the financial departments of the hospitals, and by expert opinion. **RESULTS:** The average costs per transplanted patient were €98,334 (BMT), €151,754 (MUD), and €98,977 (PBSCT) for a follow-up period of 2 years. This includes the costs of hospitalizations, medical procedures, medication, donor identification and the costs of patients who were not transplanted after they had been planned to receive an allograft. The majority of costs were made prior to and during hospitalization for graft infusion. In MUD transplantation the costs of finding a suitable donor comprise nearly one third of total costs. **CONCLUSION:** This cost analysis gives a proper indication of the costs associated with performing different types of allogeneic SCTs and maintaining a structural transplantation program in the Netherlands. The results of this analysis will be used in determining a new budget for allogeneic SCTs in the Netherlands.

#### PCN2

#### **COST-EFFECTIVENESS OF NEW CERVICAL CANCER SCREENING TECHNOLOGIES: A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION-ANALYSIS**

Sroczyński G<sup>1</sup>, Siebert U<sup>1</sup>, Voigt K<sup>2</sup>, Gibis B<sup>3</sup>, Aidelburger P<sup>4</sup>, Wasem J<sup>4</sup>, Hillemanns P<sup>2</sup>, Engel J<sup>2</sup>, Hölzel D<sup>2</sup>, Goldie S<sup>1</sup>

<sup>1</sup>Harvard School of Public Health, Boston, MA, USA;

<sup>2</sup>University Munich, Munich, Germany; <sup>3</sup>National Association of Statutory Health Insurance Physicians, Berlin, Germany;

<sup>4</sup>University of Greifswald, Greifswald, Germany

**OBJECTIVES:** The objective of this health technology assessment commissioned by the German Agency for Health Technology Assessment at DIMDI/German Federal Ministry of Health was to conduct a systematic review of the cost-effectiveness of new cervical cancer screening techniques, and to perform a decision-analysis in the context of the German health care system. **METHODS:** A systematic literature review and assessment on quality/transferability of data was performed using instruments developed by the German Scientific